Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
about
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaPersonalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisGenotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.ABCB1 genetic variants in leukemias: current insights into treatment outcomesA new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drugGenetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patientsUptake carriers and oncology drug safety.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.OCT1 and imatinib transport in CML: is it clinically relevant?Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation.ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.Predicting Chemotherapy Resistance in AML.Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia.MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia.Toward Precision Medicine: How Far Is the Goal?The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia.
P2860
Q26781539-B419A6B1-0273-4F43-8082-3797B6B38CD1Q26800005-F6912761-2F15-44FC-BA3E-FACBDC89105DQ33577088-C64FCF04-5CAD-4A26-AEF1-87E24FCBA3C3Q33707782-E6BAB48F-B081-488A-AFD4-61F880EDF2B4Q34065271-1DCD4AC4-3FC7-4A73-9CEE-1AC8A1E8569EQ36546628-D59B033E-F1D5-4C46-B7C7-B51D4596A606Q37026032-0F09B58B-5168-4D38-8BAC-0A87E5511CC1Q37207831-2B584BA1-1E05-4F19-9587-549213224B95Q37381574-BCC1C3A9-650E-4F2D-AD6F-86FAAF6CE9C3Q37663396-BB1D6934-1AAA-4A7B-8273-BBD7B93FA757Q38112821-35100709-3878-48C9-9F7B-728375892DE1Q38113416-04F2C51D-8B71-4355-8C3D-4E7EF3222796Q38199143-6C72EFA0-476D-4A01-94A4-CC784D78BB31Q38253243-DDF9D8DC-C74D-4BC0-83DA-0A38ABD503D2Q38540022-6EBF38DE-CD00-4C57-A15E-C2CD2CAAE55CQ38622785-B2E357A3-C9A3-4C67-AB20-9630F3DE27CAQ38797683-E8DE63B7-F3EC-41B4-BAD1-E12AFE26142CQ38826494-7FC60288-07DA-4F15-B866-C9A588CBC8FAQ38843265-DC41AC3C-4EC7-4253-9C8D-782610CEFC5FQ38848383-E7F68F3B-12EC-4496-BD03-653F035F9A93Q38859468-C16D6079-B8DB-443B-9E90-50733F441C23Q38868934-14C8EF52-BEE5-4604-BC68-3DE3DB62E96BQ38902116-D093DA7F-5CCB-4F74-89D9-6BD15883029CQ38910072-2D47A3A0-C439-4131-956F-12AE1CCAF753Q39233284-5F8A4B1C-C07F-41D4-8EF5-DBE1B514C834Q39429836-6CB9F3DD-C485-45CE-B366-10D53AC2D97DQ40721053-2F23CA37-E2C0-4F8A-9FC5-3A1360012DE2Q41144255-A32E3579-D0B3-42DB-B579-D529DDFE0E39Q41210809-0E86E672-3F64-479B-8C61-A2D36C6700F9Q42672408-6136DF2C-D203-4C2D-8E5E-9322FBD75EFAQ45790127-A6131A1C-97E8-4690-A5B3-C36F47F94EEFQ46431899-35EED2CB-8117-4673-A5F3-7E66469452C1Q47216949-9A775B8D-6A23-414B-B66D-2F366A5A46E9Q47912945-231DEF77-2E38-44A3-9442-DCDD44F0CD00Q49833785-2A4A61C1-FC3E-4BDB-AEAB-548C8BCA236DQ49888044-37AE9809-4DC1-4796-A84A-DF858DB96CD5Q50261890-F10556ED-9A89-46E0-9CCA-7AA39900A3F6Q51251518-D50F3182-031A-442E-ABDC-7B9E2151A1C1Q53083526-2305B60B-54A6-44F9-ACCA-3D30A5496311Q53803475-531C30A6-96F0-41DB-ABB0-CB6D57A7969B
P2860
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Association between imatinib t ...... ts receiving imatinib therapy.
@ast
Association between imatinib t ...... ts receiving imatinib therapy.
@en
type
label
Association between imatinib t ...... ts receiving imatinib therapy.
@ast
Association between imatinib t ...... ts receiving imatinib therapy.
@en
prefLabel
Association between imatinib t ...... ts receiving imatinib therapy.
@ast
Association between imatinib t ...... ts receiving imatinib therapy.
@en
P2093
P2860
P50
P1433
P1476
Association between imatinib t ...... ts receiving imatinib therapy.
@en
P2093
Daniela Cilloni
Dong Wook Kim
Giorgio Cantelli-Forti
Giovanni Perini
Jerald Radich
Mark Thornquist
Matt Barnett
Patrizia Hrelia
Richard Woodman
Timothy P Hughes
P2860
P304
P356
10.3324/HAEMATOL.2012.066480
P50
P577
2012-08-08T00:00:00Z